Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
AMI to become part of Enpro’s Sealing Technologies Segment
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Sirius JV will be owned 51% by Sirius and 49% by Adani
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Subscribe To Our Newsletter & Stay Updated
